Avançsa has signed a strategic agreement with REVEAL GENOMICS, a leading biotechnology company in the development of genomic tests for cancer diagnosis and personalized treatment. The operation, valued at 2 million euros, aims to boost the company’s growth and support its international expansion, consolidating it as a benchmark in precision oncology.
This alliance will enable REVEAL GENOMICS to advance in the development of new diagnostic tools based on genetic and clinical data, while strengthening its global presence. The agreement represents a key step in accelerating the company’s trajectory and consolidating its position in the field of personalized medicine.
REVEAL GENOMICS is the creator of HER2DX®, the world’s first genomic test designed specifically for patients with HER2-positive breast cancer, clinically validated and used in international medical centers. In addition, the company is working on the development of new tests for other breast cancer subtypes, such as DNADX® and TNBCDX®, with the aim of offering more accurate diagnostics and more personalized treatments.
In this way, REVEAL GENOMICS strengthens its commitment to innovation and internationalization, achieving key milestones such as obtaining CE marking, entering the U.S. Medicare health system, and expanding its portfolio of genomic tests for other types of cancer.
Clàudia Canals, General Director of Avançsa, highlights that “this agreement exemplifies our mission to support Catalan companies with high innovation potential and social impact.” Reveal Genomics, she adds, “is a clear leader in biotechnology and precision medicine, and we are proud to contribute to its growth and internationalization.”
Patricia Villagrasa, CEO and co-founder of REVEAL GENOMICS, notes that “this support allows us to move forward with greater strength in our mission to drive precision medicine and bring our diagnostic innovations to patients around the world. We will continue working to transform cancer diagnosis and treatment, with a firm commitment to offering solutions based on excellent science with high clinical impact.”
cloud technology axon
Addleshaw Goddard (AG), the London-headquartered international law fir...
Capital-Riesgo.es
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Capital-Riesgo.es - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory
